 STOCKHOLM, Jan. 16, 2023 PRNewswire BioArctic ABs publ NASDAQ Stockholm: BIOA B partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab Brand Name in the U.S.: LEQEMBITM, an investigational anti-amyloid beta Aβ protofibril1 antibody for the treatment of mild cognitive impairment MCI due to Alzheimers disease AD and mild AD ...... 